We are proud to announce that we are one
of the first practices in the North Texas area to prescribe




Before (left) and after (right) 8 weeks

The U.S. Food and Drug Administration (FDA) has approved LATISSE™ (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.


LATISSE™ is the first and only science based treatment approved by the FDA to enhance eyelash prominence as measured by increased length, thickness and darkness of the eyelashes.

Dr Agustin Gonzalez, OD. FAAO

Dr Clarissa De Paz, OD

Dr Luis Robles, MD